Central Pharmaceutical JSC No3
VN:DP3
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
49 800
62 700
|
| Price Target |
|
We'll email you a reminder when the closing price reaches VND.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DP3 stock under the Base Case scenario is hidden VND. Compared to the current market price of 51 600 VND, Central Pharmaceutical JSC No3 is hidden .
The Intrinsic Value is calculated as the average of DCF and Relative values:
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Central Pharmaceutical JSC No3
Balance Sheet Decomposition
Central Pharmaceutical JSC No3
| Current Assets | 523.2B |
| Cash & Short-Term Investments | 412.7B |
| Receivables | 59.5B |
| Other Current Assets | 50.9B |
| Non-Current Assets | 168.9B |
| PP&E | 114.7B |
| Intangibles | 20.1B |
| Other Non-Current Assets | 34.1B |
| Current Liabilities | 158.7B |
| Accounts Payable | 13.9B |
| Accrued Liabilities | 98.8B |
| Short-Term Debt | 14.3B |
| Other Current Liabilities | 31.8B |
Free Cash Flow Analysis
Central Pharmaceutical JSC No3
| VND | |
| Free Cash Flow | VND |
Earnings Waterfall
Central Pharmaceutical JSC No3
|
Revenue
|
422.5B
VND
|
|
Cost of Revenue
|
-141.7B
VND
|
|
Gross Profit
|
280.8B
VND
|
|
Operating Expenses
|
-137.7B
VND
|
|
Operating Income
|
143.1B
VND
|
|
Other Expenses
|
-14.1B
VND
|
|
Net Income
|
129.1B
VND
|
DP3 Profitability Score
Profitability Due Diligence
Central Pharmaceutical JSC No3's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Central Pharmaceutical JSC No3's profitability score is hidden . The higher the profitability score, the more profitable the company is.
DP3 Solvency Score
Solvency Due Diligence
Central Pharmaceutical JSC No3's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Central Pharmaceutical JSC No3's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DP3 Price Targets Summary
Central Pharmaceutical JSC No3
According to Wall Street analysts, the average 1-year price target for DP3 is 64 770 VND with a low forecast of 64 135 VND and a high forecast of 66 675 VND.
Dividends
Current shareholder yield for DP3 is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?